Emmaus Life SciencesEMMA +2.28% 9-Day RSI is 46.02 as of Jun. 30, 2026. The stock has 6 warning signs investors should review. Among 1,422 Biotechnology companies, Emmaus Life Sciences ranks better than 55.91% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Emmaus Life Sciences's 9-Day RSI or its related term are showing as below:
EMMA's 9-Day RSI is ranked better than 55.91% of 1422
companies
in the Biotechnology industry
Industry Median: 45.77
vs EMMA: 46.02
Emmaus Life Sciences (OTCPK:EMMA) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Emmaus Life Sciences 9-Day RSI Related Terms
EMMA vs PTIX, BZYR, RMTG: 9-Day RSI Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's 9-Day RSI falls into.
Emmaus Life Sciences (OTCPK:EMMA) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a 9-Day RSI of 46.02 as of Jun. 30, 2026. According to the industry distribution chart, Emmaus Life Sciences ranks #627 out of 1422 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Emmaus Life Sciences' 9-Day RSI too high?
Emmaus Life Sciences' current 9-Day RSI is 46.02. The Biotechnology industry median 9-Day RSI is 45.77. Emmaus Life Sciences' value of 46.02 is 0.5% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #627 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' 9-Day RSI compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #627 out of 1422 companies for 9-Day RSI. This puts Emmaus Life Sciences in the upper half of its industry. The industry median 9-Day RSI is 45.77. Emmaus Life Sciences' value of 46.02 is 0.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 45.77, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current 9-Day RSI of 46.02 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 45.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current 9-Day RSI is 46.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 2.3% above its estimated fair value. The current 9-Day RSI is 46.02 and 0.5% above the Biotechnology industry median of 45.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current 9-Day RSI is 46.02 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your